Furthermore, BDCA-2 has been proposed as a novel target for therapy in autoimmune diseases (i.e. systemic lupus erythematosus) [140, 141] and monoclonal antibodies targeting BDCA-2 could represent a treatment option in patients with hematologic malignancies [140–142]. Here, CLEC4C is linked to autoimmune disease.